Table 1 Comparison between none sarcopenia and sarcopenia.
From: ALBI-sarcopenia score as a predictor of treatment outcomes in hepatocellular carcinoma
None (n = 149) | Sarcopenia (n = 113) | Test of Sig. | P | |
|---|---|---|---|---|
Gender | ||||
Male | 96 (52.7%) | 86 (47.3%) | χ2 = 4.131 | 0.042* |
Female | 53 (66.3%) | 27 (33.8%) | ||
Number of Fls | ||||
Mean ± SD. | 1.71 ± 0.87 | 2.07 ± 1.05 | U = 6740.5* | 0.003* |
Median (Min–Max.) | 2 (1–6) | 2 (1–6) | ||
Size of Fls | ||||
Mean ± SD. | 3.88 ± 1.79 | 5.0 ± 3.24 | U = 6945.5* | 0.015* |
Median (Min–Max.) | 3.40 (1.30–11.0) | 4.0 (1.70–15.0) | ||
Co-morbidity | ||||
Diabetes mellitus | 47 (58.8%) | 33 (41.3%) | χ2 = 0.166 | 0.684 |
Obesity | 86 (74.1%) | 30 (25.9%) | χ2 = 25.305* | < 0.001* |
BMI (kg/m2) | ||||
Mean ± SD. | 25.15 ± 2.45 | 23.25 ± 2.14 | t = 6.564* | < 0.001* |
Median (Min–Max.) | 25.0 (21.0–33.0) | 23.0 (19.0–29.0) | ||
Nutritional status | 29 (70.7%) | 12 (29.3%) | χ2 = 3.808 | 0.051 |
Performance status | ||||
PS0 | 105 (66.9%) | 52 (33.1%) | χ2 = 16.899* | < 0.001* |
PS1 | 34 (44.7%) | 42 (55.3%) | ||
PS2 | 10 (34.5%) | 19 (65.5%) | ||
